A comprehensive haplotype analysis of CYP19 and breast cancer risk: The Multiethnic Cohort

Human Molecular Genetics

Volumn 12, Issue 20, 2003, Pages 2679-2692

  Haiman, Christopher A ^a   Stram, Daniel O ^a   Pike, Malcolm C ^a   Kolonel, Laurence N ^b   Burtt, Noel P ^c   Altshuler, David ^c,d,e   Hirschhorn, Joel ^c,d,f   Henderson, Brian E ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b UNIVERSITY OF HAWAII CANCER CENTER   (United States)

^c WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH   (United States)

^d HARVARD MEDICAL SCHOOL   (United States)

^e MASSACHUSETTS GENERAL HOSPITAL   (United States)

^f BOSTON CHILDREN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AROMATASE;

ADULT; AGED; ALLELE; ARTICLE; BREAST CANCER; CANCER RISK; CANCER SUSCEPTIBILITY; CASE CONTROL STUDY; CAUCASIAN; COHORT ANALYSIS; CONFIDENCE INTERVAL; CONTROLLED STUDY; DISEASE ASSOCIATION; ETHNOLOGY; FEMALE; FREQUENCY ANALYSIS; GENE LINKAGE DISEQUILIBRIUM; GENE LOCUS; GENETIC CONSERVATION; GENETIC PREDISPOSITION; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; GENOTYPE; HAPLOTYPE; HETEROZYGOTE; HUMAN; JAPAN; NEGRO; NUCLEOTIDE SEQUENCE; POPULATION GENETICS; PRIORITY JOURNAL; RISK ASSESSMENT; SINGLE NUCLEOTIDE POLYMORPHISM; SOUTH AND CENTRAL AMERICA; STATISTICAL ANALYSIS; UNITED STATES;

ADULT; AGED; ALLELES; AROMATASE; BREAST NEOPLASMS; CASE-CONTROL STUDIES; COHORT STUDIES; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HAPLOTYPES; HUMANS; LINKAGE DISEQUILIBRIUM; MIDDLE AGED; MODELS, GENETIC; MUTATION; POLYMORPHISM, SINGLE NUCLEOTIDE; RISK; TIME FACTORS;

HAWAIIA;

EID: 0142154271     PISSN: 09646906     EISSN: None     Source Type: Journal    
DOI: 10.1093/hmg/ddg294     Document Type: Article

References (48)

1. Henderson, B.E., Ross, R.K., Pike, M.C. and Casagrande, J.T. (1982) Endogenous hormones as a major factor in human cancer. Cancer Res., 42, 3232-3239.
2. Thomas, H.V., Reeves, G.K. and Key, T.J. (1997) Endogenous estrogen and postmenopausal breast cancer: a quantitative review. Cancer Causes Control, 8, 922-928.
3. Hankinson, S.E., Willett, W.C., Manson, J.E., Colditz, G.A., Hunter, D.J., Spiegelman, D., Barbieri, R.L. and Speizer, F.E. (1998) Plasma sex steroid hormone levels and risk of breast cancer in postmenopausal women. J. Natl Cancer Inst., 90, 1292-1299.
4. Means, G.D., Mahendroo, M.S., Corbin, C.J., Mathis, J.M., Powell, F.E., Mendelson, C.R. and Simpson, E.R. (1989) Structural analysis of the gene encoding human aromatase cytochrome P- 450, the enzyme responsible for estrogen biosynthesis. J. Biol. Chem., 264, 19385-19391.
5. Mahendroo, M.S., Means, G.D., Mendelson, C.R. and Simpson, E.R. (1991) Tissue-specific expression of human P-450AROM. The promoter responsible for expression in adipose tissue is different from that utilized in placenta. J. Biol. Chem., 266, 11276-11281.
6. Means, G.D., Kilgore, M.W., Mahendroo, M.S., Mendelson, C.R. and Simpson, E.R. (1991) Tissue-specific promoters regulate aromatase cytochrome P450 gene expression in human ovary and fetal tissues. Mol. Endocrinol., 5, 2005-2013.
7. Sasano, H., Nagura, H., Harada, N., Goukon, Y. and Kimura, M. (1994) Immunolocalization of aromatase and other steroidogenic enzymes in human breast disorders. Hum. Pathol., 25, 530-535.
8. Utsumi, T., Harada, N., Maruta, M. and Takagi, Y. (1996) Presence of alternatively spliced transcripts of aromatase gene in human breast cancer. J. Clin. Endocrinol. Metab., 81, 2344-2349.
9. Yue, W., Wang, J.P., Hamilton, C.J., Demers, L.M. and Santen, R.J. (1998) In situ aromatization enhances breast tumor estradiol levels and cellular proliferation. Cancer Res., 58, 927-932.
10. Maggiolini, M., Bonofiglio, D., Pezzi, V., Carpino, A., Marsico, S., Rago, V., Vivacqua, A., Picard, D. and Ando, S. (2002) Aromatase overexpression enhances the stimulatory effects of adrenal androgens on MCF7 breast cancer cells. Mol. Cell Endocrinol., 193, 13-18.
11. van Landeghem, A.A., Poortman, J., Nabuurs, M. and Thijssen, J.H. (1985) Endogenous concentration and subcellular distribution of estrogens in normal and malignant human breast tissue. Cancer Res., 45, 2900-2906.
12. Harada, N., Utsumi, T. and Takagi, Y. (1993) Tissue-specific expression of the human aromatase cytochrome P-450 gene by alternative use of multiple exons 1 and promoters, and switching of tissue-specific exons 1 in carcinogenesis. Proc. Natl Acad. Sci. USA, 90, 11312-11316.
13. Agarwal, V.R., Bulun, S.E., Leitch, M., Rohrich, R. and Simpson, E.R. (1996) Use of alternative promoters to express the aromatase cytochrome P450 (CYP19) gene in breast adipose tissues of cancer-free and breast cancer patients. J. Clin. Endocrinol. Metab., 81, 3843-3849.
14. Goss, P.E. and Strasser, K. (2001) Aromatase inhibitors in the treatment and prevention of breast cancer. J. Clin. Oncol., 19, 881-894.
15. Bonneterre, J., Thurlimann, B., Robertson, J.E., Krzakowski, M., Mauriac, L., Koralewski, R., Vergote, I., Webster, A., Steinberg, M. and von Euler, M. (2000) Anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in 668 postmenopausal women: results of the Tamoxifen or Arimidex Randomized Group Efficacy and Tolerability study. J. Clin. Oncol., 18, 3748-3757.
16. Nabholtz, J.M., Buzdar, A., Pollak, M., Harwin, W., Burton, G., Mangalik, A., Steinberg, M., Webster, A. and von Euler, M. (2000) Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: results of a North American multicenter randomized trial. Arimidex Study Group. J. Clin. Oncol., 18, 3758-3767.
17. Mouridsen, H., Gershanovich, M., Sun, Y., Perez-Carrion, R., Boni, C., Monnier, A., Apffelstaedt, J., Smith, R., Sleeboom, H.P., Janicke, F. et al. (2001) Superior efficacy of letrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer: results of a phase III study of the International Letrozole Breast Cancer Group. J. Clin. Oncol., 19, 2596-2606.
18. Kristensen, V.N., Andersen, T.I., Lindblom, A., Erikstein, B., Magnus, P. and Borresen-Dale, A.L. (1998) A rare CYP19 (aromatase) variant may increase the risk of breast cancer. Pharmacogenetics, 8, 43-48.
19. Siegelmann-Danieli, N. and Buetow, K.H. (1999) Constitutional genetic variation at the human aromatase gene (Cyp19) and breast cancer risk. Br. J. Cancer, 79, 456-463.
20. Probst-Hensch, N.M., Ingles, S.A., Diep, A.T., Haile, R.W., Stanczyk, F.Z., Kolonel, L.N. and Henderson, B.E. (1999) Aromatase and breast cancer susceptibility. Endocr. Relat. Cancer, 6, 165-173.
21. Haiman, C.A., Hankinson, S.E., Spiegelman, D., De Vivo, I., Colditz, G.A., Willett, W.C., Speizer, F.E. and Hunter, D.J. (2000) A tetranucleotide repeat polymorphism in CYP19 and breast cancer risk. Int. J. Cancer, 87, 204-210.
22. Healey, C.S., Dunning, A.M., Durocher, F., Teare, D., Pharoah, P.D., Luben, R.N., Easton, D.F. and Ponder, B.A. (2000) Polymorphisms in the human aromatase cytochrome P450 gene (CYP19) and breast cancer risk. Carcinogenesis, 21, 189-193.
23. Daly, M.J., Rioux, J.D., Schaffner, S.F., Hudson, T.J. and Lander, E.S. (2001) High-resolution haplotype structure in the human genome. Nat. Genet., 29, 229-232.
24. Gabriel, S.B., Schaffner, S.F., Nguyen, H., Moore, J.M., Roy, J., Blumenstiel, B., Higgins, J., DeFelice, M., Lochner, A., Faggart, M. et al. (2002) The structure of haplotype blocks in the human genome. Science, 296, 2225-2229.
25. Patil, N., Berno, A.J., Hinds, D.A., Barrett, W.A., Doshi, J.M., Hacker, C.R., Kautzer, C.R., Lee, D.H., Marjoribanks, C., McDonough, D.P. et al. (2001) Blocks of limited haplotype diversity revealed by high-resolution scanning of human chromosome 21. Science, 294, 1719-1723.
26. Pike, M.C., Kolonel, L.N., Henderson, B.E., Wilkens, L.R., Hankin, J.H., Feigelson, H.S., Wan, P.C., Stram, D.O. and Nomura, A.M. (2002) Breast cancer in a multiethnic cohort in Hawaii and Los Angeles: risk factor-adjusted incidence in Japanese equals and in Hawaiians exceeds that in whites. Cancer Epidemiol. Biomarkers Prev., 11, 795-800.
27. Harada, N. (1988) Cloning of a complete cDNA encoding human aromatase: immunochemical identification and sequence analysis. Biochem. Biophys. Res. Commun., 156, 725-732.
28. Miyoshi, Y., Iwao, K., Ikeda, N., Egawa, C. and Noguchi, S. (2000) Breast cancer risk associated with polymorphism in CYP19 in Japanese women. Int. J. Cancer, 89, 325-328.
29. Nativelle-Serpentini, C., Lambard, S., Seralim, G.E. and Sourdaine, P. (2002) Aromatase and breast cancer: W39R, an inactive protein. Eur. J. Endocrinol, 146, 583-589.
30. Kristensen, V.N., Anderson, T.I., Lindblom, L., Erikstein, B., Magnus, P. and Börrensen-Dale, A.L. (1998) A rare CYP19 (aromatase) variant may increase the risk of breast cancer. Pharmacogenetics, 8, 43-48.
31. Haiman, C.A., Hankinson, S.E., Spiegelman, D., Brown, M. and Hunter, D.J. (2002) No association between a single nucleotide polymorphism in CYP19 and breast cancer risk. Cancer Epidemiol. Biomarkers Prev., 11, 215-216.
32. Reich, D.E., Cargill, M., Bolk, S., Ireland, J., Sabeti, P.C., Richter, D.J., Lavery, T., Kouyoumjian, R., Farhadian, S.F., Ward, R. and Lander, E.S. (2001) Linkage disequilibrium in the human genome. Nature, 411, 199-204.
33. Carlson, C.S., Eberle, M.A., Rieder, M.J., Smith, J.D., Kruglyak, L. and Nickerson, D.A. (2003) Additional SNPs and linkage-disequilibrium analyses are necessary for whole-genome association studies in humans. Nat. Genet., 33, 518-521.
34. Johnson, G.C.L., Esposito, L., Barratt, B.J., Smith, A.N., Heward, J., Di Genova, G., Ueda, H., Cordell, H.J., Eaves, I.A., Dudbridge, F. et al. (2001) Haplotype tagging for the identification of common disease genes. Nat. Genet., 29, 233-237.
35. Stram, D.O., Haiman, C.A., Hirschhorn, J., Altshuler, D., Kolonel, L.N., Henderson, B.E., Pike, M.C. (2003) Choosing haplotype-tagging SNPs based on unphased genotype data from a preliminary sample of unrelated subjects with an example from the Multiethnic Cohort Study. Hum. Hered., 100, 27-36.
36. Mullis, P.E., Yoshimura, N., Kuhlmann, B., Lippuner, K., Jaeger, P. and Harada, H. (1997) Aromatase deficiency in a female who is compound heterozygote for two new point mutations in the P450arom gene: impact of estrogens on hypergonadotropic hypogonadism, multicystic ovaries, and bone densitometry in childhood. J. Clin. Endocrinol. Metab., 82, 1739-1745.
37. Henderson, B.E. and Feigelson, H.S. (2000) Hormonal carcinogenesis. Carcinogenesis, 21, 427-433.
38. Watanabe, J., Harada, N., Suemasu, K., Higashi, Y., Gotoh, O. and Kawajiri, K. (1997) Arginine-cysteine polymorphism at codon 264 of the human CYP19 gene does not affect aromatase activity. Pharmacogenetics, 7, 419-424.
39. Lee, K.M., Abel, J., Ko, Y., Harth, V., Park, W.Y., Seo, J.S., Yoo, K.Y., Choi, J.Y., Shin, A., Ahn, S.H. et al. (2003) Genetic polymorphisms of cytochrome P450 19 and 1B1, alcohol use, and breast cancer risk in Korean women. Br. J. Cancer, 88, 675-678.
40. Cox, N.J., Frigge, M., Nicolae, D.L., Concannon, P., Hanis, C.L., Bell, G.I. and Kong, A. (1999) Loci on chromosomes 2 (NIDDM1) and 15 interact to increase susceptibility to diabetes in Mexican Americans. Nat. Genet., 21, 213-215.
41. Kolonel, L.N., Henderson, B.E., Hankin, J.H., Nomura, A.M., Wilkens, L.R., Pike, M.C., Stram, D.O., Monroe, K.R., Earle, M.E. and Nagamine, F.S. (2000) A multiethnic cohort in Hawaii and Los Angeles: baseline characteristics. Am. J. Epidemiol., 151, 346-357.
42. Lewontin, R.C. (1964) The interaction of selection and linkage. I. General considerations; heterotic models. Genetics, 49, 49-67.
43. Excoffier, L. and Slatkin, M. (1995) Maximum-likelihood estimation of molecular haplotype frequencies in a diploid population. Mol. Biol. Evol., 12, 921-927.
44. Zhang, K., Deng, M., Chen, T., Waterman, M.S. and Sun, F. (2002) A dynamic programming algorithm for haplotype block partitioning. Proc. Natl Acad. Sci. USA, 99, 7335-7339.
45. Ke, X. and Cardon, L.R. (2003) Efficient selective screening of haplotype tag SNPs. Bioinformatics, 19, 287-288.
46. Zaykin, D.V., Westfall, P.H., Young, S.S., Karnoub, M.A., Wagner, M.J. and Ehm, M.G. (2002) Testing association of statistically inferred haplotypes with discrete and continuous traits in samples of unrelated individuals. Hum. Hered., 53, 79-91.
47. Stram, D.O., Pearce, C.L., Bretsky, P., Freedman, M., Hirschhorn, J., Altshuler, D., Kolonel, L.N. and Henderson, B.E. (2003) Modeling and E-M estimation of haplotype-specific relative risks from genotype data for a case-control study of unrelated individuals. Hum. Hered. (in press).
48. SAS Institute (2001) SAS release 8.02. SAS Inc., Cary, NC.